On November 13, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase II clinical study of the medicinal product AB5080.
Protocol FLU-AV5080-02 “Multicenter, randomized, double-blind, placebo-controlled study to assess efficacy, safety and optimal dose of the drug AB5080 in patients with influenza”.
The study objective is to evaluate the efficacy, safety and optimal dose of the drug AB5080 in patients with influenza.
Therapeutic area: infectious diseases.
АВ5080 is an innovative Russian drug developed by CDRI JSC and belonging to the class of neuraminidase inhibitors (modern agents with proven efficacy for the treatment of influenza.